Phase IIb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TB
2011

Adjunct Immunotherapy for Tuberculosis

Sample size: 34 publication Evidence: moderate

Author Information

Author(s): Butov Dmitry A, Pashkov Yuri N, Stepanenko Anna L, Choporova Aleksandra I, Butova Tanya S, Batdelger Dendev, Jirathitikal Vichai, Bourinbaiar Aldar S, Zaitzeva Svetlana I

Primary Institution: Kharkov National Medical University

Hypothesis

Can the oral immune adjunct V5 improve the treatment outcomes in patients with tuberculosis compared to placebo?

Conclusion

The study found that V5 is safe and can significantly enhance treatment outcomes for tuberculosis patients.

Supporting Evidence

  • 78.3% of patients on V5 had negative sputum smears after treatment.
  • V5 recipients gained an average of 3.5 kg in body weight.
  • Significant improvements in liver size and function were observed in V5 recipients.

Takeaway

This study tested a new medicine called V5 to help people with tuberculosis get better faster, and it worked well without causing any harm.

Methodology

A randomized, placebo-controlled trial with 34 adults receiving either V5 or placebo alongside standard anti-TB therapy for one month.

Potential Biases

Potential bias due to the involvement of authors who are affiliated with the company producing V5.

Limitations

The study had a small sample size and was conducted at a single center.

Participant Demographics

34 adults, 7 females and 27 males, aged 20-60 years.

Statistical Information

P-Value

0.002; 0.03; 8.3E-007; 2.8E-005; 0.002; 2.3E-009; 0.009; 6E-010

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1476-8518-9-3

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication